Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1,887

To determine the long-term cost-benefit of intravenous immunoglobulin (IVIG) treatment in Children with Kawasaki Disease (KD), a model was made to compare the total cost for management of these children with and without the use of IVIG. Long-term (10−21 years) follow-up of 594 KD patients treated in the pre-IVIG era reported by Kato, et al. was used to calculate cost using previous cost studies from Chulalongkorn Hospital. Reduction of CAA from 25 per cent to 4 per cent with IVIG treatment was assumed based on previous published data. Total cost was slightly lower for the non-IVIG treatment group compared to the IVIG treatment group (33,451,129 baht vs 35,001,195 baht) for the duration of follow-up in Kato’s model. Cost per effectiveness analysis showed more effectiveness in the IVIG treatment group (359,576 baht vs 383,614 baht). Net cost analysis similarly demonstrated lower costs in the IVIG treatment group (25,365,215 baht vs 33,451,129 baht). Incremental cost-effectiveness analysis demonstrated supplementary costs of 13,663 baht for one case in the reduction of coronary involvement and 387,517 baht for one life saved in the IVIG-treated group. Estimation of total costs for follow-up and treatment for healthy life (until 60 years old) was more expensive in the non-IVIG treatment than the IVIG treated group (75,482,803 baht vs 29,883,833 baht). The authors conclude that treatment of all KD cases in Thailand with IVIG is likely to result in lower cost and better outcome when compared to no treatment with the IVIG policy.

Read more | >

Five months into the global outbreak, the world is racing against time to prepare a vaccine for coronavirus. Trials are underway in laboratories across the world with several companies and governments doubling their efforts to find a permanent cure for the deadly virus. World leaders and organisations, except the United States, have already pledged $8 billion to research, manufacture and distribute a possible vaccine and treatments for COVID-19 apart from the individual efforts taken by the countries and its pharmaceutical firms. We take a look at what are the major developments of the coronavirus vaccine happening across the globe.

ALSO READ:Coronavirus: Google announces May 22 as company holiday to tackle WFH burnout.

Read more | >

After studying global data from the novel coronavirus (COVID-19) pandemic, researchers have discovered a strong correlation between severe vitamin D deficiency and mortality rates.

Led by Northwestern University, the research team conducted a statistical analysis of data from hospitals and clinics across China, France, Germany, Italy, Iran, South Korea, Spain, Switzerland, the United Kingdom (UK) and the United States.

The researchers noted that patients from countries with high COVID-19 mortality rates, such as Italy, Spain and the UK, had lower levels of D compared to patients in countries that were not as severely affected.

Read more | >

The new coronavirus invades the body through a spike protein that lives on the surface of virus cells. The S protein, as it’s called, binds to a receptor called angiotensin-converting enzyme 2 (ACE2) on a healthy cell’s surface. Once attached, the cells fuse and the virus is able to infect the healthy cell.

ACE2 receptors are present on cells in many places throughout the body, and especially in the lungs. Cells in the lungs are also some of the first to encounter the virus, since the primary form of transmission is thought to be breathing in droplets after an infected person has coughed or sneezed.

That’s why it was necessary to upgrade Stem Cell Neurotherapy for COVID-19 by adding T-Cells, B-Cells, and Natural Killer Cells to the arsenal. It was not enough to just regenerate new lung cells to replace the lung cells infected by COVID-19, but the COVID-19 Virus Cells had to be attacked and destroyed in order to prevent them from invading and infecting the newly regenerated lung cells.

So, that’s where the idea of using T-Cells, B-Cells, and Natural Killer Cells, usually used in attacking cancer cells, came from.

A patent has been granted by the Ministry of Economy for the development of an innovative and promising treatment for COVID-19 infections using stem cells. The treatment was developed by a team of doctors and researchers at the Abu Dhabi Stem Cell Center, ADSCC, and involves extracting stem cells from the patient’s own blood and reintroducing them after activating them.

The patent was granted for the innovative method in which the stem cells are collected.

Continue reading “Breakthrough COVID-19 treatment developed by UAE stem cell center with promising initial results” | >

Stem Cell Neurotherapy, which has achieved successful results with Parkinson’s, Essential Tremor, and Brain Tumor, can generate new cells and tissues in the lungs, liver, kidney, etc., to replace those cells and tissues that have been infected by COVID-19. This will improve the lung microenvironment, protect lung alveoli epithelial cells, and restore healthy functioning lungs.

These new cells will eliminate the fever, coughing, headaches, breathing problems, and other symptoms related to COVID-19.

At the 9:03 minute mark on the Stem Cell Neurotherapy recording, you will hear the therapeutic message:

“Your stem cells are going to transform themselves into new lung, liver, kidney, and other cells to replace those cells that have been infected by the Coronavirus. This will eliminate the inflammation, fever, breathing difficulties, coughing, and other symptoms caused by the virus.

Your body is going to produce healing hormones, messenger molecules, and proteins which will transform the stem cells into mature, well-functioning connections and tissues. These new cells and tissues are going to replace those cells and tissues that have been infected by the virus.

Your stem cells are going to transform themselves into T-Cells, B-Cells, and Natural Killer Cells, which will seek out, identify, attack, and destroy all the Coronavirus cells in your entire body.”

Continue reading “Stem cell ‘mist’ cured COVID-19 patients in the Middle East, doctors say. Here’s how” | >

face_with_colon_three could heal body parts in humans.

The generation of human induced pluripotent stem cells (iPSCs) from somatic cells using gene transfer opens new areas for precision medicine with personalized cell therapy and encourages the discovery of essential platforms for targeted drug development. iPSCs retain the genome of the donor, may regenerate indefinitely, and undergo differentiation into virtually any cell type of interest using a range of published protocols. There has been enormous interest among researchers regarding the application of iPSC technology to regenerative medicine and human disease modeling, in particular, modeling of neurologic diseases using patient-specific iPSCs. For instance, Parkinson’s disease, Alzheimer’s disease, and spinal cord injuries may be treated with iPSC therapy or replacement tissues obtained from iPSCs. In this review, we discuss the work so far on generation and characterization of iPSCs and focus on recent advances in the use of human iPSCs in clinical setting.

Stem cells exhibit the capacity of self-renewal and may undergo differentiation into various tissue types. These are divided into pluripotent stem cells (PSCs; embryonic stem cells [ESCs] and induced pluripotent stem cells [iPSCs]) and multipotent stem cells (adult stem cells [ASCs]) based on their differentiation capacity [45]. PSCs, including ESCs derived from embryos and iPSCs derived by gene transfer, may undergo indefinite proliferation and differentiate into different types of tissues depending on the treatment conditions [86]. Multipotent stem cells, however, may be obtained from tissue-derived precursors (umbilical cord blood, bone marrow, adipose tissue, placenta, or blood), which are already grown tissues.

Read more | >